KR102502745B1 - 고형종양 진단을 위한 바이오마커 절대 정량 방법 및 장치 - Google Patents

고형종양 진단을 위한 바이오마커 절대 정량 방법 및 장치 Download PDF

Info

Publication number
KR102502745B1
KR102502745B1 KR1020207002341A KR20207002341A KR102502745B1 KR 102502745 B1 KR102502745 B1 KR 102502745B1 KR 1020207002341 A KR1020207002341 A KR 1020207002341A KR 20207002341 A KR20207002341 A KR 20207002341A KR 102502745 B1 KR102502745 B1 KR 102502745B1
Authority
KR
South Korea
Prior art keywords
marker
sample
analysis
quantitative
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207002341A
Other languages
English (en)
Korean (ko)
Other versions
KR20200020906A (ko
Inventor
젠디 장
Original Assignee
옌타이 콴티시젼 다이애그노틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 옌타이 콴티시젼 다이애그노틱스 인크. filed Critical 옌타이 콴티시젼 다이애그노틱스 인크.
Publication of KR20200020906A publication Critical patent/KR20200020906A/ko
Application granted granted Critical
Publication of KR102502745B1 publication Critical patent/KR102502745B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G01N33/57484—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020207002341A 2017-06-29 2018-06-28 고형종양 진단을 위한 바이오마커 절대 정량 방법 및 장치 Active KR102502745B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762526425P 2017-06-29 2017-06-29
US62/526,425 2017-06-29
PCT/US2018/040075 WO2019006156A1 (en) 2017-06-29 2018-06-28 APPARATUS AND METHOD FOR ABSOLUTE QUANTIFICATION OF BIOMARKERS FOR SOLID TUMOR DIAGNOSIS

Publications (2)

Publication Number Publication Date
KR20200020906A KR20200020906A (ko) 2020-02-26
KR102502745B1 true KR102502745B1 (ko) 2023-02-23

Family

ID=64734814

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207002341A Active KR102502745B1 (ko) 2017-06-29 2018-06-28 고형종양 진단을 위한 바이오마커 절대 정량 방법 및 장치

Country Status (8)

Country Link
US (2) US10788484B2 (https=)
EP (1) EP3646328A4 (https=)
JP (1) JP7194128B2 (https=)
KR (1) KR102502745B1 (https=)
CN (1) CN110753845B (https=)
CA (1) CA3101968A1 (https=)
SG (1) SG11201908865WA (https=)
WO (1) WO2019006156A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201602882VA (en) 2013-10-18 2016-05-30 Univ Health Network Treatment for pancreatic cancer
KR20180135481A (ko) * 2016-04-21 2018-12-20 이매틱스 바이오테크놀로지스 게엠베하 흑색종 및 기타 암에 대한 면역요법
DE102016209871A1 (de) 2016-06-06 2017-12-07 Robert Bosch Gmbh Stanzvorrichtung und Verfahren zum Stanzen eines Lumens und Implantieren einer Implantateinrichtung
DE102018201030B4 (de) * 2018-01-24 2025-10-16 Kardion Gmbh Magnetkuppelelement mit magnetischer Lagerungsfunktion
DE102018206731A1 (de) 2018-05-02 2019-11-07 Kardion Gmbh Vorrichtung zur induktiven Energieübertragung in einen menschlichen Körper und Verwendung der Vorrichtung
DE102018206724A1 (de) 2018-05-02 2019-11-07 Kardion Gmbh Energieübertragungssystem und Verfahren zur drahtlosen Energieübertragung
DE102018206727A1 (de) 2018-05-02 2019-11-07 Kardion Gmbh Energieübertragungssystem und Empfangseinheit zur drahtlosen transkutanen Energieübertragung
DE102018206754A1 (de) 2018-05-02 2019-11-07 Kardion Gmbh Verfahren und Vorrichtung zur Bestimmung der Temperatur an einer Oberfläche sowie Verwendung des Verfahrens
DE102018206750A1 (de) 2018-05-02 2019-11-07 Kardion Gmbh Vorrichtung zur induktiven Energieübertragung in einen menschlichen Körper und deren Verwendung
DE102018206725A1 (de) 2018-05-02 2019-11-07 Kardion Gmbh Empfangseinheit, Sendeeinheit, Energieübertragungssystem und Verfahren zur drahtlosen Energieübertragung
DE102018207575A1 (de) 2018-05-16 2019-11-21 Kardion Gmbh Magnetische Stirndreh-Kupplung zur Übertragung von Drehmomenten
DE102018207611A1 (de) 2018-05-16 2019-11-21 Kardion Gmbh Rotorlagerungssystem
DE102018207594A1 (de) 2018-05-16 2019-11-21 Kardion Gmbh Rotor, Magnetkupplungsvorrichtung, Elektromotor für ein Herzunterstützungssystem, Pumpeneinheit für ein Herzunterstützungssystem sowie Verfahren zum Herstellen eines Rotors
DE102018208541A1 (de) 2018-05-30 2019-12-05 Kardion Gmbh Axialpumpe für ein Herzunterstützungssystem und Verfahren zum Herstellen einer Axialpumpe für ein Herzunterstützungssystem
DE102018208538A1 (de) 2018-05-30 2019-12-05 Kardion Gmbh Intravasale Blutpumpe und Verfahren zur Herstellung von elektrischen Leiterbahnen
DE102018208549A1 (de) 2018-05-30 2019-12-05 Kardion Gmbh Elektronikmodul für ein Herzunterstützungssystem und Verfahren zum Herstellen eines Elektronikmoduls für ein Herzunterstützungssystem
DE102018208550A1 (de) 2018-05-30 2019-12-05 Kardion Gmbh Leitungsvorrichtung zum Leiten eines Blutstroms für ein Herzunterstützungssystem, Herzunterstützungssystem und Verfahren zum Herstellen einer Leitungsvorrichtung
DE102018208539A1 (de) 2018-05-30 2019-12-05 Kardion Gmbh Motorgehäusemodul zum Abdichten eines Motorraums eines Motors eines Herzunterstützungssystems und Herzunterstützungssystem und Verfahren zum Montieren eines Herzunterstützungssystems
DE102018208555A1 (de) 2018-05-30 2019-12-05 Kardion Gmbh Vorrichtung zum Verankern eines Herzunterstützungssystems in einem Blutgefäß, Verfahren zum Betreiben und Herstellverfahren zum Herstellen einer Vorrichtung und Herzunterstützungssystem
DE102018210058A1 (de) 2018-06-21 2019-12-24 Kardion Gmbh Statorschaufelvorrichtung zur Strömungsführung eines aus einer Austrittsöffnung eines Herzunterstützungssystems ausströmenden Fluids, Herzunterstützungssystem mit Statorschaufelvorrichtung, Verfahren zum Betreiben einer Statorschaufelvorrichtung und Herstellverfahren
DE102018210076A1 (de) 2018-06-21 2019-12-24 Kardion Gmbh Verfahren und Vorrichtung zum Erkennen eines Verschleißzustands eines Herzunterstützungssystems, Verfahren und Vorrichtung zum Betreiben eines Herzunterstützungssystems und Herzunterstützungssystem
WO2020010163A1 (en) * 2018-07-02 2020-01-09 Tempus Labs, Inc. 3d radiomic platform for imaging biomarker development
DE102018211297A1 (de) 2018-07-09 2020-01-09 Kardion Gmbh Herzunterstützungssystem und Verfahren zur Überwachung der Integrität einer Haltestruktur eines Herzunterstützungssystems
DE102018211328A1 (de) 2018-07-10 2020-01-16 Kardion Gmbh Laufradgehäuse für ein implantierbares, vaskuläres Unterstützungssystem
DE102018211327A1 (de) 2018-07-10 2020-01-16 Kardion Gmbh Laufrad für ein implantierbares, vaskuläres Unterstützungssystem
DE102018212153A1 (de) 2018-07-20 2020-01-23 Kardion Gmbh Zulaufleitung für eine Pumpeneinheit eines Herzunterstützungssystems, Herzunterstützungssystem und Verfahren zum Herstellen einer Zulaufleitung für eine Pumpeneinheit eines Herzunterstützungssystems
EP3833410B1 (de) 2018-08-07 2025-10-08 Kardion GmbH Lagervorrichtung für ein herzunterstützungssystem und verfahren zum spülen eines zwischenraums in einer lagervorrichtung für ein herzunterstützungssystem
WO2021087477A1 (en) 2019-11-01 2021-05-06 Quanticision Diagnostics Inc. Method for diagnosis of cancer based on quantitative biomarkers and a database thereof
AU2021207312A1 (en) * 2020-01-17 2022-06-30 Universität Zürich Single cell pathology analysis of tumour samples
DE102020102474A1 (de) 2020-01-31 2021-08-05 Kardion Gmbh Pumpe zum Fördern eines Fluids und Verfahren zum Herstellen einer Pumpe
AU2021340802A1 (en) 2020-09-14 2023-05-18 Kardion Gmbh Cardiovascular support pump having an impeller with a variable flow area
US11699551B2 (en) 2020-11-05 2023-07-11 Kardion Gmbh Device for inductive energy transmission in a human body and use of the device
AU2021383931A1 (en) 2020-11-20 2023-07-06 Kardion Gmbh Mechanical circulatory support system with guidewire aid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140227372A1 (en) 2011-05-25 2014-08-14 Novartis Ag Biomarkers for lung cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1544618B1 (en) * 2002-07-25 2009-03-18 Ajinomoto Co., Inc. Method of analyzing protein
DE60200248T2 (de) * 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
DE102005023011A1 (de) * 2005-05-19 2006-11-23 Qiagen Gmbh Quantitative Proteinbestimmung von Formalin fixiertem Gewebe
CA2653398A1 (en) * 2006-05-26 2007-12-06 Board Of Regents, The University Of Texas System Reverse phase protein array, protein activation and expression signatures, and associated methods
GB0611669D0 (en) * 2006-06-13 2006-07-19 Astrazeneca Uk Ltd Mass spectrometry biomarker assay
WO2008075664A1 (ja) * 2006-12-21 2008-06-26 Ajinomoto Co., Inc. 癌の評価方法、ならびに癌評価装置、癌評価方法、癌評価システム、癌評価プログラムおよび記録媒体
EP2660596B1 (en) * 2008-10-02 2018-06-13 Gaia Medical Institute Health test for a broad spectrum of health problems
EP2239675A1 (en) 2009-04-07 2010-10-13 BIOCRATES Life Sciences AG Method for in vitro diagnosing a complex disease
JP2013099253A (ja) * 2010-03-11 2013-05-23 Intec Systems Institute Inc 肺癌または子宮頸癌の診断マーカー
US8293487B1 (en) 2012-01-06 2012-10-23 Jiandi Zhang Zestern, a simple, fast, specific and quantifiable improvement of immunodetection process
WO2016172216A1 (en) * 2015-04-20 2016-10-27 The Methodist Hospital Use of soluble crkl compositions as breast cancer biomarkers and predictors of cancer metastasis
US9933418B2 (en) * 2015-05-26 2018-04-03 Quanticision Diagnostics Inc. Multi-unit plate for electroblotting and immunoblot analysis
JP7144935B2 (ja) * 2015-05-29 2022-09-30 ジェネンテック， インコーポレイテッド 癌のための治療方法及び診断方法
AU2017278261A1 (en) 2016-06-05 2019-01-31 Berg Llc Systems and methods for patient stratification and identification of potential biomarkers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140227372A1 (en) 2011-05-25 2014-08-14 Novartis Ag Biomarkers for lung cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Guillemin et al., Journal of Physiology and Pharmacology, Vol. 60, Suppl. 3, 2009, pp. 91-97.
Venugopal et al., Clinical Proteomics, Vol. 10, No. 3, 2013.

Also Published As

Publication number Publication date
CN110753845B (zh) 2023-08-22
JP7194128B2 (ja) 2022-12-21
US20210011010A1 (en) 2021-01-14
CN110753845A (zh) 2020-02-04
CA3101968A1 (en) 2019-01-03
US20190004037A1 (en) 2019-01-03
US10788484B2 (en) 2020-09-29
JP2020526747A (ja) 2020-08-31
WO2019006156A1 (en) 2019-01-03
EP3646328A1 (en) 2020-05-06
SG11201908865WA (en) 2019-10-30
KR20200020906A (ko) 2020-02-26
EP3646328A4 (en) 2021-04-21

Similar Documents

Publication Publication Date Title
KR102502745B1 (ko) 고형종양 진단을 위한 바이오마커 절대 정량 방법 및 장치
Brennan et al. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology
JP2016538545A (ja) 肝臓癌の診断及び予後判定のための材料及び方法
Roe et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study
JP5370826B2 (ja) 癌の組織型を判別するカクテル抗体、判別キット及び判別方法
JP2022153460A (ja) 膀胱がんのバイオマーカーとしてのケラチン１７
EP3861348A1 (en) Biomarker combinations for determining aggressive prostate cancer
Okada et al. Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma
Sigstad et al. The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors
Rampaul et al. HER-2 in breast cancer—methods of detection, clinical significance and future prospects for treatment
DK2551673T3 (en) Methods for detecting cancer infiltration in the central nervous system
Sanchez et al. Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas
Partyka et al. Comparison of surgical and endoscopic sample collection for pancreatic cyst fluid biomarker identification
Moelans et al. Validation of a fully automated HER2 staining kit in breast cancer
US11791043B2 (en) Methods of prognosing early stage breast lesions
Sarli et al. Relationship study of the verified human epidermal growth factor receptor 2 amplification with other tumor markers and clinicohistopathological characteristics in patients with invasive breast cancer, using chromogenic in situ hybridization
CN111208304B (zh) 肿瘤来源IgG在甲状旁腺癌诊断和预后中的用途
Bogen et al. Recent trends and advances in immunodiagnostics of solid tumors
JP5130465B2 (ja) 肝細胞癌マーカー及び肝細胞癌の検査方法
Hewitt et al. Validation of proteomic‐based discovery with tissue microarrays
US20140113385A1 (en) Compositions and Methods for Identifying Single Antigens or Other Molecules in Cell Preparations
Liu et al. Establishment and application of immunohistochemical positive controls: Based on tissue fragment suspensions and tissue microarrays
Pan et al. Translation Research of Novel Biomarker
Rhodes et al. Quality assurance of predictive markers in breast cancer
Kannan STATISTICAL ANALYSIS OF 100 BREAST CANCER CASES WITH EVALUATION OF HER2/NEU STATUS IMMUNOHISTOCHEMISTRY CORRELATION WITH GENE AMPLIFICATION BY FLUORESCENCE IN SITU HYBRIDIZATION ASSAY

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000